Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine

Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies. These molecular treatments are a relatively new class of drugs for the prevention of migraine. It is likely that we will see this side effect more often in the future. Patients with a background of Raynaud's phenomenon may experience worsening of their symptoms if started on these treatments.

Automated summary

Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies, and patients with a background of Raynaud's phenomenon may experience worsening of their symptoms if started on these treatments in the future.